Form 4/A for DFTX Definium Therapeutics, Inc.
Accepted 2022-06-06 00:00:00 ET · period of report 2022-06-01 · accession 0001209191-22-034503 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2022-06-06 | 2022-06-01 | DFTX | Makes Brigid | Dir | A - Grant | $0.00 | +64.7K | 158.7K | +69% | $0 |
| DMA | 2022-06-06 | 2022-06-01 | DFTX | Makes Brigid | Dir | A - Grant | $0.00 | +462.0K | 194.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Subordinate Voting Shares | 2022-06-01 | A | A | 64,656 | $0.00 | 158,706 | D | — | — | |
| 2 | Derivative | Director's Deferred Share Units | 2022-06-01 | A | A | 361,680 | — | 643,804 | D | — · — to — | — Subordinate Voting Shares | (F4) Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-06-01 | A | A | 100,308 | $0.00 | 194,358 | D | $0.6 · — to 2027-05-31 | 100,308 Subordinate Voting Shares | (F2) The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. (F3) 1/3rd of the shares underlying the option vest and become exercisable on June 1, 2023; the remaining 2/3rds of the shares underlying the option shall vest in equal installments, vesting at the end of each month thereafter for the succeeding 24 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. |